trending Market Intelligence /marketintelligence/en/news-insights/trending/z4uW1V3dI2Mlj3B-f6k88A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Marinus seeks to raise $65M via common stock offering, private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Marinus seeks to raise $65M via common stock offering, private placement

Marinus Pharmaceuticals Inc. plans to raise about $65 million in gross proceeds from a public offering of its common stock and a concurrent private placement.

The Radnor, Pa.-based pharmaceuticals company is offering 28 million shares for $1.25 each as part of its underwritten public offering. Underwriters have also been given a 30-day option to buy up to an additional 4.2 million common shares from the company, Marinus said in a Dec. 11 press release.

Meanwhile, certain investors have agreed to purchase a total of $30 million worth of preferred shares.

Net proceeds from the common stock offering and the private placement will be primarily used to further the clinical development of the company's postpartum depression drug ganaxolone, which failed to best placebo during the second part of a mid-stage clinical trial in July.

Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. were the joint book-running managers, while Craig-Hallum Capital Group LLC acted as co-manager for the offering, expected to close Dec. 13.